^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    SSAT activator

    Related drugs:
    9ms
    Preclinical evaluation of the efficacy of α-Difluoromethylornithine and Sulindac against SARS-CoV-2 infection. (PubMed, bioRxiv)
    The treatment regime was ineffective in suppressing SARS-CoV-2 infection in K18-hACE2 mice. Overall, animal studies demonstrated the protective age- and sex-dependent antiviral efficacy of DFMO and Sulindac against SARS-CoV-2.
    Preclinical • Journal
    |
    ACE2 (Angiotensin Converting Enzyme 2)
    |
    Flynpovi (eflornithine/sulindac)
    2years
    PACES: S0820, Adenoma and Second Primary Prevention Trial (clinicaltrials.gov)
    P3, N=354, Active, not recruiting, SWOG Cancer Research Network | Recruiting --> Active, not recruiting | N=1340 --> 354
    Enrollment closed • Enrollment change
    |
    Flynpovi (eflornithine/sulindac)